





Stellarex™ DCB with EnduraCoat™ Technology


DELIVERING TOP-TIER CLINICAL OUTCOMES AT THE LOWEST THERAPEUTIC DRUG DOSE WITH THE RIGHT DRUG FORMULATION AND THE RIGHT EXCIPIENT.

EnduraCoat Technology = Hybrid Paclitaxel + Polyethylene Glycol Excipient

- + Hybrid formulation of amorphous and small-to-large crystalline paclitaxel (PTX) provides prompt drug availability and sustained tissue residency.
- + Polyethylene Glycol (PEG) excipient has a high molecular weight (8000), resulting in excellent adhesion, flexibility, elongation and elasticity.
- + PEG's exceptional durability during handling, tracking and inflation helps prevent premature drug loss.



PEG
INCREASES FLEX, TORQUE AND COMPRESSION DURING TRACKING.



SMALL MOLECULE
LESS DURABLE DURING HANDLING, TRACKING AND INFLATION.


Affinity to Calcified Lesions



PEG FORMS STRONG IONIC BONDS WITH HYDROXYL APATITE (HAp), THE PRIMARY COMPONENT OF CALCIFIED ATHEROSCLEROTIC LESIONS.²

PEG'S AFFINITY FOR HAp MAY RESULT IN LIMITED PTX WASHOUT IN THE PRESENCE OF CALCIUM.

Lutonix®




MOSTLY AMORPHOUS PTX
2µg/mm²

Prompt availability and
short-term tissue residency

POLYSORBATE, SORBITOL
EMULSIFIER EXCIPIENT

Small molecular weight: 1310 + 182




Emulsifier helps water-insoluble
materials like PTX dissolve
quickly in water

May reduce amount of available PTX

Theoretically, these are headwinds
against getting the drug to the lesion

Stellarex™



HYBRID AMORPHOUS + CRYSTALLINE PTX
2µg/mm²

Prompt availability and
long-term tissue residency

POLYETHYLENE GLYCOL (PEG)
POLYMER EXCIPIENT

Large molecular weight: 8000




Dissolves slowly to protect PTX from premature
washoff, keeping more drug at the lesion, which
may allow for lowest therapeutic drug dose

Increased durability during
flexion, torque and compression

More durability during handling,
tracking and inflation

Natural affinity to calcified lesions

In.Pact™



MOSTLY CRYSTALLINE PTX
3.5µg/mm²

Delayed availability and
long-term tissue residency

UREA
SMALL MOLECULE EXCIPIENT

Small molecular weight: 60




Dissolves quickly, which may expose
brittle crystalline PTX to blood flow

Possible increased PTX
exposure downstream

Less durability during handling,
tracking and inflation


Low Particulate Loss

Stellarex demonstrates minimal particulate loss, reducing the risk of downstream embolization. EnduraCoat Technology provides coating stability, which enables a low therapeutic drug dose.



High Transfer Efficiency and Effective Residency

Stellarex EnduraCoat Technology achieves uniform and acute drug transfer and sustained tissue residency at therapeutic levels through 28 days.



For important safety information, please visit www.spectranetics.com/IFU

References

¹ Mark J, et al. Physical properties of polymers. Cambridge University Press. 3rd ed. 2004.

² Venkatasubbu GD, et al. Surface modification and paclitaxel drug delivery of folic acid modified polyethylene glycol functionalized hydroxyapatite nanoparticles. Powder Technology. 2013;235:437-442.

³ Superimposed PK curves from different data sets: Melder R. EuroPCR 2012, Yazdani, et al. Catheterization and Cardiovascular Interventions. 2014;83:132-140. Data on file at Spectranetics.

⁴ Data on file at Spectranetics.

Corporate Headquarters

The Spectranetics Corporation, 9065 Federal Drive, Colorado Springs, CO 80921
Tel: 719-447-2000 | Fax: 719-447-2022 | Customer Service: 800-231-0973

Learn more and come visit us at www.stellarexpcb.com

©2017 Spectranetics. All Rights Reserved. Approved for External Distribution. D037362-01 072017

 **Spectranetics®**
Always Reaching Farther